Proudly presenting ERA4Health project HFpEF-DIVA Consortium (2024-2027):  Diverging HFpEF Phenotypes : patient-tailoreD targeting of anti-Inflammatory pathways to limit Ventricular and Atrial remodelling

Dr Ebba Brakenhielm Coordinator: EnVI Laboratory, INSERM UMR1096 Rouen, France	Dr Vanessa van Empel Partner 2:   Maastricht University Department of Cardiology, CARIM, Netherlands	Pr Arantxa González-Miqueo Partner 3: CIMA, Pamplona, Spain       .	Pr Elizabeth Jones Partner 4:  KU Leuven, Belgium	Dr Jean-Christophe Rain Partner 5: Hybrigenics SAS, Evry, France	Krista Bogaert Collaborator I:  Healthy Heart Fund, Leuven, Belgium

Read more: ERA4HEALTH Joint Action 

Twitter / X: #HFpEF_DIVA 

LinkedIn: https://fr.linkedin.com/company/hfpef-diva  

Acute decompensated heart failure (ADHF) represents a major therapeutic challenge. Although numerous well-established therapies are available in the clinic for chronic HF, the acute HF market has considerable unmet needs. Cardiac edema may be a key-player in this pathophysiological situation, and we hypothesize that loss of microvascular integrity in blood vessels and lymphatics contributes to cardiac edema in ADHF. We have previously shown that prevention of vascular hyperpermeability reduces cardiac edema acutely post-MI.

In this project, coordinated by Dr Stephane Germain (Collège de France) and in collaboration with Pr Bijan Ghaleh-Marzban (Mondor Biomedical Institute) and Pr Paul Mulder and Dr Ebba Brakenhielm at Inserm UMR 1096, we investigate, in our novel ADHF models, the contribution of microvascular leakage and/or lymphatic dysfunction to cardiac edema; and further determine if restoration of vascular integrity (Patent, Partner 1; Project coordinator) may reduce blood microvascular hyperpermeability, lymphatic dysfunction as well as cardiac edema and lead to improved cardiac functional recovery.

Our RESIST-HF project, focused on restoring microvascular integrity, will improve the understanding of ADHF mechanisms and may reveal new and efficient pharmacological strategies to improve patient outcome.

See REStoring mIcrovaScular inTegrity in acute Heart Failure | ANR

The ANR PRC project MiRAVALVE-CKD  - Mineralocorticoid Receptor Antagonism and Aortic Valve Calcification in Chronic Kidney Diseases has been selected for funding. This project, coordinated by Pr Frédéric Jaisser at the Centre de Recherche des Cordeliers , Inserm UMR S1138, in collaboration with Pr Paul Mulder, Inserm UMR1096 and Pr Natalia López-Andrés, Navarra University, Spain, is set to investigate the impact of the mineralocorticoid system in mediating valcular calcification in the setting of chronic kidney disease.

Dr Ebba Brakenhielm is Coordinator on an ANR international collaborative project entitled CITE-LYMPH : «Ciblage lymphatique cardiaque des cellules immunitaires» selected in the ANR PRCI 2022 axis «Collaboration bilatérale ANR/ DFG»

This project is developed together with Pr Alma Zernecke-Madsen (Institut für Experimentelle Biomedizin der Universität Würzburg, Germany).